Category Archives: Transhuman News

DAVIS, Calif., Feb. 8, 2021 /PRNewswire/ --Evolve BioSystems announced today that it completed a substantial first close in a $55 million Series D round of funding, led by Cargill, the global food, agricultural, financial and industrial products company and Manna Tree, an investment firm committed to improving human health. The new capital will be used to help the companycontinue commercializing a next generation of probiotic capable of addressing a widespread deficiency in the infant gut microbiome.

"We are thrilled to announce our newest investors as we continue our quest to address this health crisis in newborns," said Timothy Brown, CEO of Evolve BioSystems. "Our research found that more than 90 percent of infants in the U.S. are missing the critical bacteria, Bifidobacterium longum subsp. infantis (B. infantis), which is widely documented as a key component of the infant gut microbiome. The financial support announced today, which includes strong continued support from our earlier investors, will help continue our mission to make a healthier future for our children during infancy and beyond."

Evolve BioSystems manufactures Evivo, a proprietary groundbreaking probiotic proven to resolve infant gut dysbiosis, or Newborn Gut Deficiency. Evivo is comprised of activated B. infantis EVC001, which studies have shown guides critical development of infants' digestive and immune systems. Evivo restores this missing bacterium to the infant gut microbiome, reducing potentially pathogenic bacteria by 80 percent as well as significantly reducing intestinal inflammation. These pathogens are linked to higher risk of both short- and long-term health issues including colic, diaper rash, eczema, asthma, allergies and Type 1 Diabetes.

"Evivo, Evolve BioSystem's innovative infant probiotic, has been proven to have a dramatic impact on the developing infant gut, and to guide long-term health trajectory. This round of financing will continue to raise consumer and health care practitioner awareness, while supporting continued research and development. We are proud to partner with innovators like Tim and the entire Evolve team who are at the forefront of food and biotechnology" said Gabrielle "Ellie" Rubenstein, Co-Founder and CEO of Manna Tree. "This important investment is at the very core of our mission at Manna Tree - investing in human health."

The health benefits of Evivo are documented through numerous clinical studies and peer-reviewed publications. The investments of Manna Tree and Cargill come on the heels of the most recent breakthrough in the Evolve research, the U.S. Microbiome Survey, recently published in Scientific Reports. The research shows that nine out of ten U.S. infants are suffering from Newborn Gut Deficiency, increasing risk to early infant health and development. The study is the largest to date to benchmark the widespread levels of potential pathogenic bacteria in U.S. infants and the substantial deficiency B. infantis.

"Evolve BioSystem's Evivo has the potential to be a highly distinctive probiotic for infants and we are delighted to work with them to scale its impact," said Chuck Warta, president of Cargill's health technologies business. "Our goal is to help humans live more healthy days right from the start. Together, we can harness our respective expertise and knowledge in nutrition, digestive and immune health to bring next generation ingredient solutions to our customers."

Through its collaboration with the Bill & Melinda Gates Foundation, Evolve BioSystems is currently involved in a clinical trial at the International Centre for Diarrheal Disease Research in Bangladesh to assess the impact of Evivo on infants who have been diagnosed with severe acute malnutrition.

As part of the investment, Cargill and Manna Tree will serve as lead investors and join the company's board of directors. Other Evolve BioSystems investors in this round include Horizons Ventures, Johnson & Johnson Innovation JJDC, Inc., Spruce Capital Partners, Acre Venture Partners and Bow Capital. Evolve was spun-off from the Foods for Health Institute (FFHI) at the University of California, Davis in 2014.

For more information on Evolve BioSystems and Evivo, visit http://www.evolvebiosystems.com or http://www.evivo.com. To learn more about the Evolve BioSystems investors, visit Manna Tree at http://www.mannatreepartners.comandwww.Cargill.com.

About Evolve BioSystems, Inc

Evolve BioSystems, Inc. is a privately held microbiome company dedicated to researching solutions to establish, restore, and maintain a healthy gut microbiome. Evolve is a portfolio company of Cargill, Manna Tree, the Bill & Melinda Gates Foundation and Horizons Ventures, the venture division of the Li Ka Shing Foundation. Evolve is a spin-off from the Foods for Health Institute (FFHI) at the University of California, Davis and builds on more than a decade of research into understanding the unique partnership of the infant gut microbiome and breast milk components.

About Cargill

Cargill's 155,000 employees across 70 countries work relentlessly to achieve our purpose of nourishing the world in a safe, responsible and sustainable way. Every day, we connect farmers with markets, customers with ingredients, and people and animals with the food they need to thrive.

We combine 155 years of experience with new technologies and insights to serve as a trusted partner for food, agriculture, financial and industrial customers in more than 125 countries. Side-by-side, we are building a stronger, sustainable future for agriculture. For more information, visitCargill.comand ourNews Center.

About Manna Tree

Manna Tree is a Vail, Colorado-based investment firm committed to improving human health through nutrition. The firm invests in and actively partners with growth-stage companies. We believe the future of health, well-being and longevity is attainable through innovation in food. Manna Tree has $235 million in assets under management, as of September 2020, and has made five investments to date: Vital Farms, Verde Farms, MycoTechnology, Nutriati, and Gotham Greens. http://www.mannatreepartners.com.

SOURCE Evolve BioSystems

Read the rest here:
Evolve BioSystems Announces Major Strategic Investment from Cargill and Manna Tree to Support Innovative Probiotic That Dramatically Improves Infant...

Through centuries of evolution, the human body and its surrounding environments have adapted to improve health and promote longevity. For example, the increasing emphasis on hygiene has been effective in combating parasites that cause disease.

These changes have been crucial, as evidenced by the greater life expectancies and lower disease rates in certain regions of the world. However, these benefits come with trade-offs.

Parasites and humans share a long history of coexistence. It is likely that the human immune function developed in relation to parasitic mechanisms.

The old friends hypothesis states that these parasites were like old friends of the human body that helped improve tolerance and function and that their decline led to a higher prevalence of allergic responses and autoimmune conditions.

This decline may also promote inflammaging, which is a chronic form of inflammation that worsens with progressing age. Inflammaging contributes to several age-related conditions, such as dementia, cancer, osteoporosis, and heart disease.

One recent study shows that inflammaging may exacerbate symptoms of COVID-19, as well.

Bruce Zhang and Dr. David Gems, from the Institute of Healthy Ageing at University College London in the United Kingdom, conducted a review of the existing literature to explore the use of parasite worms as a therapy to reverse conditions linked to inflammaging. This review article appears in the journal eLife.

The authors focused their research on a specific group of parasitic worms called helminths, which include roundworms, tapeworms, and flukes. These parasites live inside host organisms, such as human bodies, and take advantage of their immune responses in order to survive.

These findings also provide a glimpse into the intricacies of the human bodys immune functions.

Scientists associate the decline of helminths with multiple inflammatory conditions that occur earlier in life. These include asthma, eczema, multiple sclerosis (MS), rheumatoid arthritis, inflammatory bowel disease, and type 1 diabetes.

Current evidence supports the idea that both natural and deliberate infection with helminths can combat these inflammatory conditions.

Indeed, in 1976, researcher J. A. Turton published a report in which he explained that his hookworm infection reduced the severity of his allergies.

A more recent study which Marc Charabati, of the University of Montreal in Canada, led showed that infecting mice with helminths eased their MS symptoms.

Although these findings suggest that restorative helminth therapy may address pre-aging inflammatory conditions, the question of whether or not it can prevent conditions that occur in older age remains.

A key characteristic of inflammaging is a consistent increase in pro-inflammatory proteins in the blood. Multiple experiments have shown that helminth infection can suppress levels of these pro-inflammatory proteins.

In contrast, administering anthelmintic treatments which can kill helminths increased the inflammatory response of these proteins.

Although the direct administration of helminths can be beneficial, it can also cause undesired infections. A viable alternative is to utilize the molecular components of helminth mechanisms.

One experiment, which Jenny Crowe and others at the University of Glasgow in the U.K. conducted, incorporated this concept in a mouse model that ate a high calorie diet. Specifically, the team administered a protein called ES-62, which is an anti-inflammatory molecule derived from roundworm secretion.

They found that ES-62 prevented both the degradation of the gut barrier and the enlargement of fat tissue, which are mechanisms that contribute to inflammaging.

The mice also showed a 12% increase in their median lifespan. This suggests that ES-62 was able to suppress inflammaging and limit health-related age acceleration.

Similar studies have indicated the effectiveness of helminths and helminth-secreted products in protecting against rheumatoid arthritis, atherosclerosis, and type 2 diabetes.

There is also some evidence that points to helminth therapy in cancer resistance. A few studies in mice have shown that tapeworms prevented the formation of colon tumors.

However, it is important to note that certain helminths can cause cancer, as well. For example, the trematode parasite Schistosoma haematobium can cause bladder cancer.

Although these studies do not confirm that helminths can directly reduce inflammaging, they do show the ability of helminths to protect against the processes that ultimately lead to it.

Zhang and Dr. Gems raise important questions regarding helminth therapy research. These include: What are optimal ages to apply such therapy to reduce inflammaging? Would helminth therapy act only in a preventive fashion (typical of anti-aging treatments), or could it reverse existing disease symptoms?

They also state the necessity of understanding the pathways that shape anti-inflammaging properties.

As Dr. Gems says, In the wake of successes during the last century in eliminating the evils of helminth infections, the time now seems propitious to explore further their possible benefits, particularly for our aging population strange though this may sound.

Read the rest here:
Parasite infections may prevent aging and disease - Medical News Today

Overview for Longevity and Anti-senescence Therapy Market Helps in providing scope and definitions, Key Findings, Growth Drivers, and Various Dynamics.

Longevity and Anti-senescence Therapy Market Data and Acquisition Research Study with Trends and Opportunities 2019-2024The study of Longevity and Anti-senescence Therapy market is a compilation of the market of Longevity and Anti-senescence Therapy broken down into its entirety on the basis of types, application, trends and opportunities, mergers and acquisitions, drivers and restraints, and a global outreach. The detailed study also offers a board interpretation of the Longevity and Anti-senescence Therapy industry from a variety of data points that are collected through reputable and verified sources. Furthermore, the study sheds a lights on a market interpretations on a global scale which is further distributed through distribution channels, generated incomes sources and a marginalized market space where most trade occurs.

Along with a generalized market study, the report also consists of the risks that are often neglected when it comes to the Longevity and Anti-senescence Therapy industry in a comprehensive manner. The study is also divided in an analytical space where the forecast is predicted through a primary and secondary research methodologies along with an in-house model.

Download PDF Sample of Longevity and Anti-senescence Therapy Market report @ https://hongchunresearch.com/request-a-sample/113635

Key players in the global Longevity and Anti-senescence Therapy market covered in Chapter 4:Acorda TherapeuticsUnity BiotechnologyAntoxereneCelgeneCohbarSenex BiotechnologyHuman Longevity Inc.T.A. SciencesAgex TherapeuticsRecursion PharmaceuticalsCalico Life SciencesSpotlight BiosciencePowervision Inc.Sierra Sciences LlcRestorbioInsilico MedicineOisin BiotechnologySenolytic TherapeuticsProteostasis Therapeutics Inc.Prana Biotechnology Ltd.Cleara Biotech

In Chapter 11 and 13.3, on the basis of types, the Longevity and Anti-senescence Therapy market from 2015 to 2026 is primarily split into:Senolytic Drug TherapyGene TherapyImmunotherapyOthers

In Chapter 12 and 13.4, on the basis of applications, the Longevity and Anti-senescence Therapy market from 2015 to 2026 covers:LongevitySenescence InhibitionCardiovascular DiseasesNeural Degenerative DiseasesOphthalmology DisordersCancer

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:North America (Covered in Chapter 6 and 13)United StatesCanadaMexicoEurope (Covered in Chapter 7 and 13)GermanyUKFranceItalySpainRussiaOthersAsia-Pacific (Covered in Chapter 8 and 13)ChinaJapanSouth KoreaAustraliaIndiaSoutheast AsiaOthersMiddle East and Africa (Covered in Chapter 9 and 13)Saudi ArabiaUAEEgyptNigeriaSouth AfricaOthersSouth America (Covered in Chapter 10 and 13)BrazilArgentinaColumbiaChileOthersRegional scope can be customized

For a global outreach, the Longevity and Anti-senescence Therapy study also classifies the market into a global distribution where key market demographics are established based on the majority of the market share. The following markets that are often considered for establishing a global outreach are North America, Europe, Asia, and the Rest of the World. Depending on the study, the following markets are often interchanged, added, or excluded as certain markets only adhere to certain products and needs.

Here is a short glance at what the study actually encompasses:Study includes strategic developments, latest product launches, regional growth markers and mergers & acquisitionsRevenue, cost price, capacity & utilizations, import/export rates and market shareForecast predictions are generated from analytical data sources and calculated through a series of in-house processes.

However, based on requirements, this report could be customized for specific regions and countries.

Brief about Longevity and Anti-senescence Therapy Market Report with [emailprotected]https://hongchunresearch.com/report/longevity-and-anti-senescence-therapy-market-size-2020-113635

Some Point of Table of Content:

Chapter One: Report Overview

Chapter Two: Global Market Growth Trends

Chapter Three: Value Chain of Longevity and Anti-senescence Therapy Market

Chapter Four: Players Profiles

Chapter Five: Global Longevity and Anti-senescence Therapy Market Analysis by Regions

Chapter Six: North America Longevity and Anti-senescence Therapy Market Analysis by Countries

Chapter Seven: Europe Longevity and Anti-senescence Therapy Market Analysis by Countries

Chapter Eight: Asia-Pacific Longevity and Anti-senescence Therapy Market Analysis by Countries

Chapter Nine: Middle East and Africa Longevity and Anti-senescence Therapy Market Analysis by Countries

Chapter Ten: South America Longevity and Anti-senescence Therapy Market Analysis by Countries

Chapter Eleven: Global Longevity and Anti-senescence Therapy Market Segment by Types

Chapter Twelve: Global Longevity and Anti-senescence Therapy Market Segment by Applications 12.1 Global Longevity and Anti-senescence Therapy Sales, Revenue and Market Share by Applications (2015-2020) 12.1.1 Global Longevity and Anti-senescence Therapy Sales and Market Share by Applications (2015-2020) 12.1.2 Global Longevity and Anti-senescence Therapy Revenue and Market Share by Applications (2015-2020) 12.2 Longevity Sales, Revenue and Growth Rate (2015-2020) 12.3 Senescence Inhibition Sales, Revenue and Growth Rate (2015-2020) 12.4 Cardiovascular Diseases Sales, Revenue and Growth Rate (2015-2020) 12.5 Neural Degenerative Diseases Sales, Revenue and Growth Rate (2015-2020) 12.6 Ophthalmology Disorders Sales, Revenue and Growth Rate (2015-2020) 12.7 Cancer Sales, Revenue and Growth Rate (2015-2020)

Chapter Thirteen: Longevity and Anti-senescence Therapy Market Forecast by Regions (2020-2026) continued

Check [emailprotected] https://hongchunresearch.com/check-discount/113635

List of tablesList of Tables and Figures Table Global Longevity and Anti-senescence Therapy Market Size Growth Rate by Type (2020-2026) Figure Global Longevity and Anti-senescence Therapy Market Share by Type in 2019 & 2026 Figure Senolytic Drug Therapy Features Figure Gene Therapy Features Figure Immunotherapy Features Figure Others Features Table Global Longevity and Anti-senescence Therapy Market Size Growth by Application (2020-2026) Figure Global Longevity and Anti-senescence Therapy Market Share by Application in 2019 & 2026 Figure Longevity Description Figure Senescence Inhibition Description Figure Cardiovascular Diseases Description Figure Neural Degenerative Diseases Description Figure Ophthalmology Disorders Description Figure Cancer Description Figure Global COVID-19 Status Overview Table Influence of COVID-19 Outbreak on Longevity and Anti-senescence Therapy Industry Development Table SWOT Analysis Figure Porters Five Forces Analysis Figure Global Longevity and Anti-senescence Therapy Market Size and Growth Rate 2015-2026 Table Industry News Table Industry Policies Figure Value Chain Status of Longevity and Anti-senescence Therapy Figure Production Process of Longevity and Anti-senescence Therapy Figure Manufacturing Cost Structure of Longevity and Anti-senescence Therapy Figure Major Company Analysis (by Business Distribution Base, by Product Type) Table Downstream Major Customer Analysis (by Region) Table Acorda Therapeutics Profile Table Acorda Therapeutics Production, Value, Price, Gross Margin 2015-2020 Table Unity Biotechnology Profile Table Unity Biotechnology Production, Value, Price, Gross Margin 2015-2020 Table Antoxerene Profile Table Antoxerene Production, Value, Price, Gross Margin 2015-2020 Table Celgene Profile Table Celgene Production, Value, Price, Gross Margin 2015-2020 Table Cohbar Profile Table Cohbar Production, Value, Price, Gross Margin 2015-2020 Table Senex Biotechnology Profile Table Senex Biotechnology Production, Value, Price, Gross Margin 2015-2020 Table Human Longevity Inc. Profile Table Human Longevity Inc. Production, Value, Price, Gross Margin 2015-2020 Table T.A. Sciences Profile Table T.A. Sciences Production, Value, Price, Gross Margin 2015-2020 Table Agex Therapeutics Profile Table Agex Therapeutics Production, Value, Price, Gross Margin 2015-2020 Table Recursion Pharmaceuticals Profile Table Recursion Pharmaceuticals Production, Value, Price, Gross Margin 2015-2020 Table Calico Life Sciences Profile Table Calico Life Sciences Production, Value, Price, Gross Margin 2015-2020 Table Spotlight Bioscience Profile Table Spotlight Bioscience Production, Value, Price, Gross Margin 2015-2020 Table Powervision Inc. Profile Table Powervision Inc. Production, Value, Price, Gross Margin 2015-2020 Table Sierra Sciences Llc Profile Table Sierra Sciences Llc Production, Value, Price, Gross Margin 2015-2020 Table Restorbio Profile Table Restorbio Production, Value, Price, Gross Margin 2015-2020 Table Insilico Medicine Profile Table Insilico Medicine Production, Value, Price, Gross Margin 2015-2020 Table Oisin Biotechnology Profile Table Oisin Biotechnology Production, Value, Price, Gross Margin 2015-2020 Table Senolytic Therapeutics Profile Table Senolytic Therapeutics Production, Value, Price, Gross Margin 2015-2020 Table Proteostasis Therapeutics Inc. Profile Table Proteostasis Therapeutics Inc. Production, Value, Price, Gross Margin 2015-2020 Table Prana Biotechnology Ltd. Profile Table Prana Biotechnology Ltd. Production, Value, Price, Gross Margin 2015-2020 Table Cleara Biotech Profile Table Cleara Biotech Production, Value, Price, Gross Margin 2015-2020 Figure Global Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure Global Longevity and Anti-senescence Therapy Revenue ($) and Growth (2015-2020) Table Global Longevity and Anti-senescence Therapy Sales by Regions (2015-2020) Table Global Longevity and Anti-senescence Therapy Sales Market Share by Regions (2015-2020) Table Global Longevity and Anti-senescence Therapy Revenue ($) by Regions (2015-2020) Table Global Longevity and Anti-senescence Therapy Revenue Market Share by Regions (2015-2020) Table Global Longevity and Anti-senescence Therapy Revenue Market Share by Regions in 2015 Table Global Longevity and Anti-senescence Therapy Revenue Market Share by Regions in 2019 Figure North America Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure Europe Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure Asia-Pacific Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure Middle East and Africa Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure South America Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure North America Longevity and Anti-senescence Therapy Revenue ($) and Growth (2015-2020) Table North America Longevity and Anti-senescence Therapy Sales by Countries (2015-2020) Table North America Longevity and Anti-senescence Therapy Sales Market Share by Countries (2015-2020) Figure North America Longevity and Anti-senescence Therapy Sales Market Share by Countries in 2015 Figure North America Longevity and Anti-senescence Therapy Sales Market Share by Countries in 2019 Table North America Longevity and Anti-senescence Therapy Revenue ($) by Countries (2015-2020) Table North America Longevity and Anti-senescence Therapy Revenue Market Share by Countries (2015-2020) Figure North America Longevity and Anti-senescence Therapy Revenue Market Share by Countries in 2015 Figure North America Longevity and Anti-senescence Therapy Revenue Market Share by Countries in 2019 Figure United States Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure Canada Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure Mexico Longevity and Anti-senescence Therapy Sales and Growth (2015-2020) Figure Europe Longevity and Anti-senescence Therapy Revenue ($) Growth (2015-2020) Table Europe Longevity and Anti-senescence Therapy Sales by Countries (2015-2020) Table Europe Longevity and Anti-senescence Therapy Sales Market Share by Countries (2015-2020) Figure Europe Longevity and Anti-senescence Therapy Sales Market Share by Countries in 2015 Figure Europe Longevity and Anti-senescence Therapy Sales Market Share by Countries in 2019 Table Europe Longevity and Anti-senescence Therapy Revenue ($) by Countries (2015-2020) Table Europe Longevity and Anti-senescence Therapy Revenue Market Share by Countries (2015-2020) Figure Europe Longevity and Anti-senescence Therapy Revenue Market Share by Countries in 2015 Figure Europe Longevity and Anti-senescence Therapy Revenue Market Share by Countries in 2019 Figure Germany Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure UK Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure France Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure Italy Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure Spain Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure Russia Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure Asia-Pacific Longevity and Anti-senescence Therapy Revenue ($) and Growth (2015-2020) Table Asia-Pacific Longevity and Anti-senescence Therapy Sales by Countries (2015-2020) Table Asia-Pacific Longevity and Anti-senescence Therapy Sales Market Share by Countries (2015-2020) Figure Asia-Pacific Longevity and Anti-senescence Therapy Sales Market Share by Countries in 2015 Figure Asia-Pacific Longevity and Anti-senescence Therapy Sales Market Share by Countries in 2019 Table Asia-Pacific Longevity and Anti-senescence Therapy Revenue ($) by Countries (2015-2020) Table Asia-Pacific Longevity and Anti-senescence Therapy Revenue Market Share by Countries (2015-2020) Figure Asia-Pacific Longevity and Anti-senescence Therapy Revenue Market Share by Countries in 2015 Figure Asia-Pacific Longevity and Anti-senescence Therapy Revenue Market Share by Countries in 2019 Figure China Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure Japan Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure South Korea Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure Australia Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure India Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure Southeast Asia Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure Middle East and Africa Longevity and Anti-senescence Therapy Revenue ($) and Growth (2015-2020) continued

About HongChun Research: HongChun Research main aim is to assist our clients in order to give a detailed perspective on the current market trends and build long-lasting connections with our clientele. Our studies are designed to provide solid quantitative facts combined with strategic industrial insights that are acquired from proprietary sources and an in-house model.

Contact Details: Jennifer GrayManager Global Sales+ 852 8170 0792[emailprotected]

NOTE: Our report does take into account the impact of coronavirus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

https://neighborwebsj.com/

Read the original:
Global Longevity and Anti-senescence Therapy Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based...